Drug Safety
11 months ago
Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation.
The better we can predict these patients, the more we can get the right therapy early
POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.
Therapeutic development in pSS appears to…
11 months ago
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
11 months ago
New 2023 @eular_org SLE recommendations
Key changes, in response to evidence:
- more caution re: steroids
- biologics earlier
- combo therapy (BEL or CNI/VCS) considered for lupus nephritis
#EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
11 months ago
#EULAR2023 recommendation update summary from the 2018 in #PsA whats new!
- 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline)
- safety now to to considered!
- consider the full picture - extraarticular manifestations
@rheumnow https://t.co/7GBILtCX4i
11 months ago
Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL Surveillance).
Real problem:
many still have shorter follow-up periods. Cancer in particular takes time. It’s great to see data now, but:
*longer follow-up needed* +++
@RheumNow https://t.co/YH4fZgNQjY
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
Rheumatoid Factor Lowering Predicts Improved Outcomes in RA. Abstract…
Rheumatoid arthritis (RA) is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic…
Podcasts
Featured BSR Abstracts (5.3.2024)
SLE Faculty Panel Q&A
Tuesday Night Rheumatology- Mastering SLE
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1601919334745-0'); });
Poster Hall